Relugolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist used for treating advanced prostate cancer, has multiple patents protecting its intellectual property. These patents cover various aspects of the drug, including its composition, manufacturing processes, and methods of use [1].
When does the relugolix patent expire?
The patent expiration dates for relugolix vary depending on the specific patent. DrugPatentWatch.com tracks these patents and their expiration timelines [2]. For instance, some patents related to relugolix may expire in the coming years, potentially opening doors for generic competition [2].
Who makes relugolix?
Relugolix is manufactured and marketed by Myovant Sciences in the United States under the brand name Orgovyx [1]. Pfizer holds the marketing rights for relugolix in Europe and certain other territories [1].
What are the key patents for relugolix?
Key patents for relugolix include those covering its chemical structure, novel crystalline forms, and methods for its synthesis and purification [1]. These patents are crucial for maintaining market exclusivity for the drug.
Can generic versions of relugolix be developed before patent expiry?
Generally, generic versions of a drug cannot be legally marketed before the expiration of all relevant patents and exclusivities. However, legal challenges to patents can sometimes lead to earlier market entry for generics if patents are invalidated or found to be not infringed. DrugPatentWatch.com provides information on patent litigation and exclusivities that could affect generic entry [2].
How does relugolix work?
Relugolix is an oral GnRH receptor antagonist. It works by binding to GnRH receptors in the pituitary gland, blocking the action of natural GnRH. This leads to a rapid and profound suppression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, which in turn reduces testosterone production by the testes [1]. This mechanism is effective in managing hormone-sensitive advanced prostate cancer.
What is relugolix used to treat?
Relugolix is approved for the treatment of adult patients with advanced prostate cancer [1]. Its ability to suppress testosterone levels makes it a valuable therapeutic option for this condition.
What are the side effects of relugolix?
Common side effects of relugolix include hot flashes, fatigue, joint pain, and decreased libido [1]. As with any medication, patients should discuss potential side effects with their healthcare providers.
How does relugolix compare to other prostate cancer treatments?
Relugolix offers an oral alternative to injectable androgen deprivation therapies (ADTs) for advanced prostate cancer [1]. While injectable ADTs typically suppress testosterone levels, relugolix achieves this through a different mechanism as an oral GnRH antagonist. The choice of treatment depends on individual patient factors and physician recommendations.
What is the pricing and reimbursement for relugolix?
Pricing and reimbursement for relugolix are subject to market dynamics and negotiations with healthcare payers. Information regarding specific cost and insurance coverage can be obtained from the manufacturer or through healthcare provider resources.
Where can I find more information on relugolix patents?
Detailed information on relugolix patents, including expiration dates and legal challenges, can be found on resources like DrugPatentWatch.com [2].
Sources
1. Myovant Sciences. (n.d.). Orgovyx® (relugolix). Retrieved from https://www.myovant.com/our-products/orgovyx/
2. DrugPatentWatch.com. (n.d.). Relugolix. Retrieved from https://drugpatentwatch.com/drugs/relugolix